Glucuronidation and Covalent Protein Binding of Benoxaprofen and Flunoxaprofen in Sandwich-Cultured Rat and Human Hepatocytes

Jennifer Q. Dong and Philip C. Smith

Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Seattle, Washington (J.Q.D.); and Eschelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (P.C.S.)

Received June 15, 2009; accepted September 17, 2009

ABSTRACT:

Benoxaprofen (BNX), a nonsteroidal anti-inflammatory drug (NSAID) that was withdrawn because of hepatotoxicity, is more toxic than its structural analog flunoxaprofen (FLX) in humans and rats. Acyl glucuronides have been hypothesized to be reactive metabolites and may be associated with toxicity. Both time- and concentration-dependent glucuronidation and covalent binding of BNX, FLX, and ibuprofen (IBP) were determined by exposing sandwich-cultured rat hepatocytes to each NSAID. The levels of glucuronide and covalent protein adduct measured in cells followed the order BNX > FLX > IBP. These results indicate that 1) BNX-glucuronide (G) is more reactive than FLX-G, and 2) IBP-G is the least reactive metabolite, which support previous *in vivo* studies in rats. The proportional increases of protein adduct formation for BNX, FLX, and IBP as acyl glucuronidation increased also support

the hypothesis that part of the covalent binding of all three NSAIDs to hepatic proteins is acyl glucuronide-dependent. Moreover, these studies confirmed the feasibility of using sandwich-cultured rat hepatocytes for studying glucuronidation and covalent binding to hepatocellular proteins. These studies also showed that these *in vitro* methods can be applied using human tissues for the study of acyl glucuronide reactivity. More BNX-protein adduct was formed in sandwich-cultured human hepatocytes than FLX-protein adduct, which not only agreed with its relative toxicity in humans but also was consistent with the *in vitro* findings using rat hepatocyte cultures. These data support the use of sandwich-cultured human hepatocytes as an *in vitro* screening model of acyl glucuronide exposure and reactivity.

Many types of acidic drugs form acyl glucuronides, and other xenobiotics are metabolized to carboxylic acids (Phase I metabolites), which subsequently undergo Phase II conjugation to form acyl glucuronides. Often such a glucuronide conjugate constitutes the major metabolite. The major site of conjugation for most compounds in humans is believed to be the liver. Modification of critical hepatic proteins by covalent binding of acidic drugs through reactive acyl glucuronides may provide a basis for direct hepatocyte toxicity or immune-mediated adverse reactions (Gillette, 1974; Faed, 1984; Boelsterli, 2002; Bailey and Dickinson, 2003).

Some pharmaceutical companies have been conducting *in vitro* experiments by incubating acyl glucuronides with model proteins or peptides (Wang et al., 2004) to determine their reactivity, and hence possibly predict the relative extent of covalent protein binding *in vivo* in humans. This method requires chemical synthesis or biosynthesis of

individual glucuronides for each drug candidate, a process that can be tedious and costly. In addition, hepatic tissue proteins are not present in the incubation, which makes it less likely to correlate covalent protein binding with hepatotoxicity. *In vitro* models involving hepatic materials, including liver homogenates, microsomal subcellular preparation, and isolated hepatocyte suspensions and cultures, offer many advantages over *in vitro* incubation with model proteins. Not only are hepatic tissue proteins present, but UDP glucuronosyltransferase (UGT) activities that catalyze the glucuronidation reactions are also maintained. However, membrane transport functions are lost or not well maintained in isolated hepatocytes or even primary hepatocyte cultures. Although the intact animal model represents undisturbed hepatic physiology, high-throughput screenings using *in vivo* studies are not very practical. Moreover, extrapolation of animal data to humans is often questionable, especially for drug metabolism.

We propose that hepatocyte culture with a “sandwich” configuration would be a good model for estimating covalent binding to hepatic tissue proteins *in vivo*. Hepatocyte monolayer is cultured between two layers of Matrigel, a matrix material resembling the mammalian cellular basement membrane, and this has been shown to prolong cell viability and has better preservation of liver-specific protein synthesis

This work was supported by the National Institutes of Health National Institute of General Medical Sciences [Grant GM61188].

Article, publication date, and citation information can be found at <http://dmd.aspetjournals.org>.
doi:10.1124/dmd.109.028944.

ABBREVIATIONS: UGT, UDP glucuronosyltransferase; BNX, benoxaprofen; FLX, flunoxaprofen; IBP, ibuprofen; HPLC, high-performance liquid chromatography; PBS, phosphate-buffered saline; SKF-525A, proadifen hydrochloride; LDH, lactate dehydrogenase; ABT, 1-aminobenzotriazole; DMEM, Dulbecco's modified Eagle's medium; MCM, modified Chee's medium; PMSF, phenylmethylsulfonyl fluoride; PH, 1,7-phenanthroline; BNX-G, benoxaprofen glucuronide; FLX-G, flunoxaprofen glucuronide; IBP-G, ibuprofen glucuronide; P450, cytochrome P450; NSAID, nonsteroidal anti-inflammatory drug.

FIG. 1. Structures of BNX and FLX. BNX was marketed as the racemate; FLX was marketed as the *S*-isomer.

than primary hepatocytes maintained under conventional culture conditions (Dunn et al., 1989, 1991). This model system uses biologically relevant matrix components and therefore is more close to the native architecture of the hepatocyte environment. A unique feature of this sandwiched culture of hepatocytes is the formation of functional bile canalicular networks formed with rat hepatocytes. In addition, the normal polarized distribution of several different classes of functionally active canalicular transport systems, such as multidrug-resistant protein 2, is also re-established in this configuration (LeCluyse et al., 1994). It has been reported that the hepatobiliary transport of reactive diclofenac glucuronide via multidrug-resistant protein 2 is critical for diclofenac covalent binding to proteins in the biliary tree (Seitz et al., 1998). In addition to being a much more biologically relevant *in vitro* model in terms of morphology and biochemical properties, this sandwiched hepatocyte culture system also maintains a better functional enzyme/transport system than microsomes, with which the hepatocytes can generate metabolites such as acyl glucuronides. Furthermore, the availability of sandwiched human hepatocyte cultures will allow *in vitro* evaluation of covalent binding in hepatocytes using human tissues. This is essential for studies of compounds that are potentially toxic to humans because direct detection of acyl glucuronide-derived drug-protein adducts in human liver is not feasible.

Benoxaprofen (BNX) and flunoxaprofen (FLX), a pair of structural analogs (Fig. 1) with different degrees of hepatotoxicity in humans and rats, were selected as model compounds. BNX was marketed as a racemic mixture, whereas FLX was marketed as the *S*-isomer only. Several reports of fatal cholestatic jaundice, often associated with nephrotoxicity, led to the withdrawal of BNX from the world market only 5 months after its launch (Dahl and Ward, 1982). However, no fatal adverse events related to FLX have been reported. We have previously shown that BNX is more reactive than FLX with human serum albumin and plasma protein *in vitro*, as well as *in vivo* in a rat model (Dong et al., 2005). Fluorescent adducts of BNX and FLX have also been detected with human plasma proteins from patients administered the drugs (Dahms and Spahn-Langguth, 1996). In this study, we first evaluated the glucuronidation and protein adduct formation of model compounds in the sandwiched rat hepatocyte culture. An *in vitro* and *in vivo* correlation in rats in terms of relative reactivity of glucuronide metabolites was then established. In addition, the effects of modulating metabolism of BNX and FLX *in vitro* on the extent of protein adduct formation were investigated. Finally, we examined the applicability of sandwiched culture of human hepatocytes in estimating the relative covalent binding to hepatic proteins. Glucuronidation and protein adduct formation of radiolabeled ibuprofen (IBP), a well tolerated drug with a low incidence of side effects, in the sandwiched rat hepatocyte culture were also determined and served as a reference. These studies show through a series of experiments with rat hepatocytes the applicability of sandwich culture hepatocytes for investigating reactive acyl glucuronides and confirm that similar studies can be conducted with human hepatocytes, thus allowing possible predictions to humans.

Materials and Methods

Materials. *Rac*-BNX was extracted and purified from tablets of Oralflex previously marketed by Eli Lilly & Co. (Indianapolis, IL). [Analysis calculated for BNX ($\text{C}_{16}\text{H}_{12}\text{ClNO}_3$): C, 63.69; H, 4.01; N, 4.64; Cl, 11.75; O, 15.91. Found: C, 63.05; H, 4.31; N, 4.71; Cl, 11.68; O, 16.25.] The purity of BNX (>99%) was confirmed based on elemental analysis and analytical high-performance liquid chromatography (HPLC) using UV detection at wavelength of 210 nm. *S*-FLX, the marketed form, was contributed by Dr. A. Forgione (Ravizza Laboratories, Milan, Italy) and was determined to be pure (>98%) based on HPLC with UV detection. IBP, Triton X-100, EDTA, glycerol, glycine, phosphate-buffered saline (PBS), borneol, SKF-525A, lactate dehydrogenase (LDH) kit, Percoll, Hanks' balanced salt solution, and dexamethasone were obtained from Sigma-Aldrich (St. Louis, MO). [^3H]IBP (1 Ci/mmol) was purchased from ICN (currently Valeant Pharmaceuticals, Costa Mesa, CA). 1,7-Phenanthroline was purchased from Aldrich Chemical Co. (Milwaukee, WI). 1-Aminobenzotriazole (ABT) was a gift from Dr. J. Mathews at Triangle Research Institute (Research Triangle Park, NC). Protogel, ammonium sulfate, TEMED, dithiothreitol, bromophenol blue, and Tris were purchased from Bio-Rad Laboratories (Hercules, CA). Collagenase was obtained from Worthington Biochemicals (Freehold, NJ). Dulbecco's modified Eagle's medium (DMEM), modified Chee's medium (MCM), fetal calf serum, and insulin were purchased from Invitrogen (Carlsbad, CA). Rat tail collagen (type I) was obtained from Collaborative Research (Bedford, MA). Matrigel was purchased from Thermo Fisher Scientific (Waltham, MA). Methanol and acetonitrile were HPLC grade from Mallinckrodt Baker, Inc. (Phillipsburg, NJ). All of the other chemicals used were of reagent grade. Male Sprague-Dawley rats (250–350 g) were supplied by Harlan (Indianapolis, IN). Experiments were approved by the university's animal care committee. Human liver microsomal preparations were obtained from BD Gentest (Woburn, MA).

Isolation and Culture of Rat Hepatocytes. Plastic culture dishes (60 mm) were precoated with rat tail collagen, type I (0.1 ml/dish, 1.5 mg/ml), in a gelled state at least 1 day before hepatocyte harvest. To obtain a gelled collagen substratum, neutralized collagen type I was prepared on ice (as described by the manufacturer's instruction) and spread onto Petri dishes with a sterile Teflon (DuPont, Wilmington, DE) policeman. Freshly coated dishes were then placed at 37°C in a humidified incubator for at least 60 min to allow the matrix material to gel, followed by addition of 3 ml of fresh medium to the dishes and storage in a humidified incubator until used. Just before cell isolation, the medium was aspirated from the precoated culture dishes.

Hepatocytes were isolated from male Sprague-Dawley rats (250–350 g b.wt.) by a modification of the two-step collagenase perfusion method as previously described by LeCluyse et al. (1994) and Liu et al. (1999). Animal studies were approved by the Institutional Animal Care and Use Committee at the university. Rats were anesthetized with ketamine/acepromazine (75:2 mg/kg, *i.m.*) before portal vein cannulation. The liver was perfused *in situ* with oxygenated calcium-free buffer containing 5.5 mM glucose, 0.5 mM EDTA, 25.0 mM sodium bicarbonate, 1.2 mM potassium phosphate, pH 7.4, 4.7 mM potassium chloride, and 118.0 mM sodium chloride for ~10 min at 37°C, followed by perfusion with buffer containing 2 mM calcium and collagenase type II (0.3 mg/ml) for 10 to 15 min. After collagenase perfusion, the digested liver was carefully removed and placed into a sterile, covered crystallization dish and transported to a sterile hood, where 30 ml of DMEM kept at room temperature and supplemented with 5% fetal calf serum, 1 μM dexamethasone, and 4 mg/l insulin was immediately added. The hepatocytes were dispersed by tearing open Glisson's capsule with the aid of two sterile forceps and gently shaking the liver until most of the cells were released into the medium. The released cells were then filtered through a sterile nylon 70- μm filter into a 250-ml beaker. Another 30 ml of medium was added to the crystallization dish, which was gently swirled to release any remaining cells from the liver remnant, and filtered as before. This rinsing step was then repeated one more time. The cell suspension was divided equally between two 50-ml sterile centrifuge tubes and centrifuged at 40g for 2 min at room temperature. The supernatant fractions were discarded, and cell pellets were gently resuspended in fresh DMEM to attain a final volume of 25 ml. An equal volume of 90% isotonic Percoll (Percoll/10 $\times$ Hanks' balanced salt solution, 9:1, *v/v*) was added to the suspension, which was mixed well by inverting the tube and centrifuged at 80g for 5 min at room temperature. The supernatant

FIG. 2. Hepatocyte cultures just before Matrigel overlay (A) or 5 days after overlay in a sandwich configuration (B).

fraction was aspirated, and the cell pellets were resuspended in a combined volume of 40 ml of medium and transferred into one 50-ml centrifuge tube. The cells were washed again by centrifugation at 60g for 2 min. The final cell pellet was resuspended gently in 40 ml of medium. Hepatocyte viability was determined by trypan blue exclusion and was typically >90%. Cells were diluted with fully supplemented medium to a cell concentration of 1.0×10^6 cells/ml, and 3-ml aliquots were seeded into 60-mm collagen-coated culture dishes. After a 2-h attachment period at 37°C in a 5% CO₂/95% air atmosphere, the medium was replaced with fresh DMEM-supplemented insulin and dexamethasone. The culture dishes were then placed in the 37°C humidified incubator for 24 h until the Matrigel overlay (Fig. 2A shows the hepatocyte morphology just before the overlay).

To prepare cultures in a sandwich configuration, the Matrigel stock solution was slowly thawed at 4°C, diluted with ice-cold MCM to a final concentration of 250 µg/ml (Sidhu et al., 1993). The medium was aspirated from culture dishes, and 3 ml of medium/Matrigel mixture was overlaid onto dishes with precooled sterile pipettes. Matrigel-treated cultures were allowed to incubate overnight. Medium was then changed daily until studies were performed. All the experiments were done in 5-day postoverlay hepatocyte cultures (Fig. 2B) and in serum-free MCM.

Studies with Rat Hepatocyte Culture. The glucuronidation and covalent protein adduct formation in rat hepatocytes were first evaluated. For time dependence studies, 500 µM BNX, FLX, or IBP was dissolved in fresh MCM and directly added to the rat hepatocyte cultures. The dose of 500 µM IBP also contained trace amounts of radiolabeled IBP (2.3 µCi of [³H]IBP/ml of culture medium). After incubation for designated times, the cultures were extensively washed with ice-cold PBS containing 0.2 mM phenylmethylsulfonyl fluoride (PMSF) to reduce possible hydrolysis of acyl glucuronides by nonspecific esterases. The cells were harvested in 2 ml of ice-cold PBS containing 0.2 mM PMSF, 1% Triton X-100, and 10 µl of 43% phosphoric acid and lysed by Polytron (Kinematica, Littau-Lucerne, Switzerland). The cell homogenates were then deproteinized by adding 4 ml of ice-cold acetonitrile (including 5 µg of internal standard) to precipitate proteins and extract unbound (not covalently bound) drug and metabolites, followed by centrifugation at 4000 rpm for 10 min. The supernatant fractions and the protein pellets were stored at -80°C until analyzed for the concentrations of acyl glucuronide and protein adduct formed, respectively.

For concentration dependence studies, cultured rat hepatocytes were incubated with various concentrations of BNX and FLX dissolved in MCM. BNX reaches peak plasma concentrations greater than 100 µM after oral doses of 600 mg to humans (Ridolfo et al., 1979), with higher concentrations expected in liver during absorption; therefore, a range of up to 1000 µM was selected for these *in vitro* studies. After 6-h exposure, the cultures were extensively washed with ice-cold PBS containing 0.2 mM PMSF, and the cells were harvested as described above. Four milliliters of ice-cold acetonitrile (20 ng, 50 ng, 2 µg, and 5 µg of internal standard were added for concentrations of 10, 100, 250, and ≥500 µM, respectively) was added to precipitate the proteins. After the centrifugation of cell homogenates, the supernatant fractions and the cell pellets were stored separately at -80°C. Cytotoxicity of BNX and FLX at the highest concentration was estimated by determining LDH release into the extracellular medium. LDH activities were determined spectrophotometrically with a Sigma-Aldrich test kit. Enzyme activity in the medium was expressed as percentage of total LDH present in the cells at the beginning of the incubation.

The effects of modulating metabolic pathways on the glucuronidation and covalent protein binding were determined. The cells were exposed to 500 µM BNX and FLX in the presence or absence of 1 mM borneol, 10 µM SKF-525A, or 1 mM ABT after preincubation with each for 30 min. Rat hepatocytes were also pretreated with 200 µM 1,7-phenanthroline (PH) for 3 days (fresh dose replaced daily), followed by the exposure of 500 µM BNX and FLX. Cells were also exposed to 500 µM IBP (containing 2.3 µCi of [³H]IBP/ml of culture medium) in the presence and absence of 1 mM borneol or 1 mM ABT after preincubation with each for 30 min. All the incubations were carried out to 6 h, at which time cells were extensively washed and harvested as described above. Supernatant fractions and protein pellets separated by centrifugation were stored at -80°C until further analysis.

HPLC analyses using the native fluorescence of BNX and FLX (details described previously by Dong et al., 2005) were carried out to determine the formation of BNX glucuronide (BNX-G) and FLX glucuronide (FLX-G) in the rat hepatocytes. The supernatant fractions of harvested cells were evaporated to dryness. The residues were reconstituted with 0.5 ml of mobile phase and injected onto HPLC. For cells incubated with 10 and 100 µM of either BNX or FLX, 100 and 10 µl of 0.5-ml reconstituted samples were injected, respectively. For cells incubated with concentrations ≥250 µM, additional dilution of reconstituted samples was made before 20 µl of the diluted samples was injected onto HPLC.

For detection of IBP glucuronide (IBP-G) formed in the rat hepatocytes, an HPLC assay (Castillo et al., 1995) was first carried out to isolate and collect the IBP-G. The HPLC equipment used was essentially the same as for BNX and FLX assays (Dong et al., 2005) but with a Hewlett-Packard (Palo Alto, CA) variable wavelength detector (set at 250 nm) replacing the Shimadzu (Kyoto, Japan) fluorescence detector. The mobile phase consisted of methanol/10 µM trifluoroacetic acid in water (60:40, v/v), and isocratic elution was performed at a flow rate of 1.2 ml/min. The IBP-G peak was then collected with a fraction collector, and the collections were evaporated to dryness under nitrogen. Aliquots of 2.5 ml of 1 M sodium hydroxide were added to dissolve the residues, which were then transferred into scintillation vials. Finally, 10 ml of Ultima Gold scintillation fluid (PerkinElmer Life and Analytical Sciences, Waltham, MA) was added, and the radioactivity was determined by liquid scintillation counting.

Irreversible binding of BNX, FLX, and IBP metabolites to hepatocellular proteins was determined as described previously (Dong et al., 2005). In brief, the protein pellets were extensively washed with methanol/ether (3:1, v/v). After centrifugation, the protein pellets were dried and incubated with 2.5 ml of 1 M sodium hydroxide at 80°C for 1 h. BNX- and FLX-protein adducts were extracted from sodium hydroxide with dichloromethane. The subsequently dried residues were reconstituted in 250 µl of proper mobile phase, and 200 µl was injected onto HPLC. IBP-protein adducts were determined by adding 10 ml of Ultima Gold scintillation fluid (PerkinElmer Life and Analytical Sciences) to the sodium hydroxide mixture. The total cell-associated radioactivity was determined by liquid scintillation counting. Total protein content per dish was determined according to Bradford (1976) using bovine serum albumin as standard protein.

Studies with Human Liver Microsomes and Human Hepatocyte Cultures. Human liver microsomes from three subjects were used. The glucuronidation of BNX and FLX in these preparations was measured similarly to that described for rat liver microsomal studies by Dong et al. (1999). In brief, microsomal protein was first incubated with Triton X-100 for 15 min at room temperature. The incubation mixture (0.5 ml) contained 2 mg/ml microsomal protein, 0.05% Triton X-100, 10 mM magnesium chloride, 100 mM Tris buffer, pH 7.4, and 0.1 to 2 mM BNX or FLX with the addition of inhibitors of hydrolytic enzymes (0.4 mM PMSF and 16 mM saccharic acid 1,4-lactone); it was then warmed to 37°C for 5 min. The reaction (over a 20-min period) was started by adding UDP-glucuronic acid (final concentration, 10 mM). Aliquots of 0.10 ml were taken from the assay mixture at various times and were pipetted into 0.20 ml of ice-cold acetonitrile (including internal standard). The pH of the samples was adjusted to 2 to 4 to further stop the reaction. After centrifugation, the supernatants were dried under nitrogen gas and reconstituted in 0.5 ml of mobile phase before injection onto the HPLC. Activities of UGT are expressed as nanomoles of BNX-G or FLX-G formed per minute per milligram of microsomal protein.

Kinetic analyses of UGT in the human liver were carried out by determining initial rates of activity at five different fixed BNX and FLX concentrations

(0.1, 0.2, 0.5, 1, and 2 mM). The initial glucuronide formation rate was determined simply by using linear regression analysis on the BNX-G and FLX-G formation over time profile. Kinetic constants ($V_{\max}$ and K_M) for UGT were first estimated by plotting the initial rate of activity and substrate concentration on double-reciprocal plots and Eadie-Hofstee plots, then determined by fitting the data to the Michaelis-Menten equation (WinNonlin 1.1; Pharsight, Mountain View, CA).

Sandwiched human hepatocyte cultures (35-year-old white male, day 4 post-Matrigel overlay, five Petri dishes) were gifts from Dr. E. LeCluyse (University of North Carolina at Chapel Hill, Chapel Hill, NC). BNX and FLX dissolved in MCM at 500 μ M were added to the cell cultures (BNX, $n = 3$; FLX, $n = 2$). After 6-h incubation, cell cultures were washed extensively, and cells were harvested and lysed as described previously. The amounts of BNX-G and FLX-G formed in the hepatocytes and the extent of covalent binding of each to hepatic cellular proteins were determined as described above.

Results

Time Dependence and Concentration Dependence of Glucuronidation and Covalent Protein Binding in Rat Hepatocyte Cultures. BNX- and FLX-induced hepatocyte injury was monitored throughout the present study to ensure that glucuronidation and covalent protein binding of BNX and FLX were not compromised as a result of acute cell injury. Exclusion of the vital dye trypan blue by the hepatocyte cultures indicated that more than 85% of the cells were still viable after treatment with various concentrations of BNX or FLX for various periods. LDH release into the extracellular medium was also measured as a marker for acute cell injury in the sandwich-cultured rat hepatocytes. In the presence of 1000 μ M (the highest concentration used in the present study) of BNX and FLX, LDH leakage in the medium was not different from that in the control cells for up to 12 h (data not shown). LDH release was increased after 24 h to $\sim$ 24 and $\sim$ 18% of total LDH activity in BNX- and FLX-treated hepatocytes, respectively, compared with $\sim$ 5% of total LDH leakage in control cells. However, when the hepatocyte cultures were exposed to 500 μ M BNX and FLX, no differences in LDH release were observed between the treated and untreated cells (data not shown), indicating that BNX and FLX treatment at the concentration of 500 μ M did not cause apparent cell injury.

Time-dependent glucuronidation of BNX, FLX, and IBP was determined by exposing cultured hepatocytes to each at 500 μ M for up to 24 h. BNX-G and FLX-G formed in the hepatocytes were quantitated by HPLC-fluorescence analysis, whereas IBP-G was first isolated by HPLC and then analyzed by liquid scintillation counting. Formations of all three glucuronides were found to increase with time, with the concentrations of BNX-G higher than FLX-G at any given time, and IBP-G was detected at the lowest level (Fig. 3). Exposure of cultured hepatocytes to BNX, FLX, and IBP was associated with the appearance of drug irreversibly bound to hepatic proteins. Covalent protein binding also accumulated over the incubation period, with the highest protein adduct concentrations detected in BNX-treated hepatocytes and the lowest in IBP-treated hepatocytes (Fig. 4). In addition, covalent binding profiles appeared to mimic their corresponding glucuronidation profiles. In fact, covalent binding was found to increase as a linear function of the acyl glucuronide concentrations (Fig. 5), indicating that the covalent adduct formation may be mediated via reactive acyl glucuronide. When normalized to glucuronide concentration, the extent of adduct formation in the rat hepatocyte cultures was highest after BNX treatment and the lowest after IBP, as indicated by trends of the slopes of linear regressions of adduct versus glucuronide concentration profiles in Fig. 5. This suggests that BNX-G is the most reactive one among the three acyl glucuronides studied in

Fig. 3. Time-dependent glucuronidation profiles of BNX, FLX, and IBP in cultured rat hepatocytes. Hepatocytes were exposed to 500 μ M BNX (■), FLX (●), and IBP (▲). At various times indicated, the cells were harvested, and the amounts of glucuronides formed were determined. Values are mean $\pm$ S.D. of triplicate incubations.

Fig. 4. Time-dependent covalent binding profiles of BNX, FLX, and IBP in cultured rat hepatocytes. Hepatocytes were exposed to 500 μ M BNX (■), FLX (●), and IBP (▲). At various times indicated, the cells were harvested, and the concentrations of protein adducts formed were determined. Values are mean $\pm$ S.D. of triplicate incubations.

this study, and IBP-G is the least reactive acyl glucuronide of the three examined here.

Concentration dependence of glucuronidation and protein adduct formation of BNX and FLX ranging from 10 to 1000 μ M was investigated at the 6-h incubation time. Nonlinear glucuronidation and protein adduct formation were observed for both BNX and FLX at concentrations higher than 100 μ M, and the maximal glucuronidation and binding were reached at an initial concentration of 750 μ M (Figs.

FIG. 5. Covalent protein binding of BNX (■), FLX (●), and IBP (▲) correlate well with their corresponding glucuronide formations in the rat hepatocyte cultures at drug concentration of 500 μ M. Slopes of the linear regressions are 13.1, 10.1, and 9.76 for BNX, FLX, and IBP, respectively.

FIG. 7. Concentration-dependent covalent binding of BNX and FLX in cultured rat hepatocytes. BNX (■) and FLX (●) were added at the concentrations indicated. After 6 h, the covalent protein adducts in the cells were determined. Values are the means $\pm$ S.D. of triplicate incubations.

FIG. 6. Concentration-dependent glucuronidation of BNX and FLX in cultured rat hepatocytes. BNX (■) and FLX (●) were added at the concentrations indicated. After 6 h, the amounts of glucuronide formed in the cells were determined. Values are the means $\pm$ S.D. of triplicate incubations.

FIG. 8. Effects of UGT inhibitor and inducer on the glucuronidation of BNX, FLX, or IBP in hepatocyte cultures. Hepatocyte cultures were incubated with 500 μ M BNX, FLX, and IBP in the absence (control) or presence of 1 mM borneol or 200 μ M PH for 6 h. For induction study, cells were also preincubated with PH for 3 days. The zero time glucuronide values were subtracted from all the data. Values are the means $\pm$ S.D. of triplicate incubations. Asterisks indicate significant difference from the appropriate control ($p < 0.05$). Note: 24-h incubation was conducted for IBP, and the effect of PH on IBP glucuronidation was not studied.

6 and 7). Higher mean levels of BNX-G and BNX-protein adduct were detected in the hepatocytes than FLX-G and FLX-protein adduct, respectively, at all the concentrations examined.

Effects of Modulating Metabolism on the Covalent Protein Binding. To assess whether covalent binding of BNX, FLX, and IBP could be mediated via another metabolic pathway other than the formation of reactive acyl glucuronides, the effects of modulating glucuronidation (with borneol and PH) and oxidative metabolism (with ABT and SKF-525A) on the covalent adduct formation were

examined. Borneol, which depletes glucuronidation cofactor UDP-glucuronic acid (Watkins and Klaassen, 1983), almost completely inhibited the formation of BNX-G, FLX-G, and IBP-G (Fig. 8). In contrast, formation of adduct with BNX, FLX, and IBP to hepatocellular proteins was only inhibited approximately half (46 and 50% for BNX and FLX, respectively) in the hepatocyte cultures when treated with borneol relative to control (Fig. 9). PH is a selective Phase II enzyme inducer and has been shown to significantly increase BNX

FIG. 9. Effects of UGT inhibitor and inducer on the covalent binding of BNX, FLX, and IBP to hepatocellular proteins. Hepatocyte cultures were incubated with 500 μ M BNX, FLX, or IBP in the absence (control) or presence of 1 mM borneol or 200 μ M PH for 6 h. For induction study, cells were also preincubated with PH for 3 days. The zero time binding values were subtracted from all the data but were generally less than 5% of the values reported. Values are the mean $\pm$ S.D. of triplicate incubations. Asterisks indicate significant difference from the appropriate control ($p < 0.05$). Note: 24-h incubation was conducted for IBP, and the effect of PH on IBP covalent protein binding was not studied.

glucuronidation in vivo in rats (Dong et al., 1999). In the present study, we found that the glucuronidation of BNX and FLX was significantly increased in hepatocyte cultures pretreated with PH (55 and 224% for BNX and FLX, respectively) compared with untreated cultures (Fig. 8). However, no effect of PH on covalent protein binding of either BNX or FLX was detected (Fig. 9). These data suggest that the covalent protein binding of BNX, FLX, and IBP is only partially mediated via the formation of reactive glucuronides.

An alternative metabolic pathway that may form reactive intermediate capable of binding covalently to proteins and releasing parent drug when treated with base was then investigated. The effects of inhibitors of cytochrome P450 (P450) activity on the glucuronidation of BNX, FLX, and IBP were first evaluated to ascertain that the P450 inhibitors did not block the glucuronidation pathway. SKF-525A and ABT, two general P450 inhibitors, did not appear to alter the glucuronidation of BNX, FLX, and IBP (Fig. 10), nor did they reduce the covalent bindings of drugs to cellular proteins (Fig. 11). These data suggest that BNX, FLX, and IBP covalent protein adducts, as measured by base hydrolysis, are not likely to be mediated via the formation of reactive oxidative metabolites.

Human UGT Activities in Liver Microsomes and Enzyme Kinetic Studies. The glucuronidation of BNX and FLX in human liver microsomes from three different donors was determined over a range of substrate concentrations. The dependence of the initial formation rates of BNX-G and FLX-G as a function of the substrate concentration is illustrated in Fig. 12, with the maximum formation rates reached at the substrate concentration of 1 mM. The extent of glucuronidation varied dramatically between donors. The UGT activity of donor 3 was very low; only a small amount of BNX-G was detected in its liver microsomal preparation, and levels of FLX-G were below the detection limit of the assay. Donors 1 and 2 appeared to have

FIG. 10. Effects of P450 inhibitors on the glucuronidation of BNX, FLX, and IBP in hepatocyte cultures. Hepatocyte cultures were incubated with 500 μ M BNX, FLX, or IBP in the absence (control) or presence of 1 mM ABT or 10 μ M SKF-525A for 6 h. The zero time glucuronide values were subtracted from all the data. Values are the mean $\pm$ S.D. of triplicate incubations. Note: 24-h incubation was conducted for IBP, and the effect of SKF-525A on IBP glucuronidation was not studied.

FIG. 11. Effects of P450 inhibitors on the covalent binding of BNX, FLX, and IBP to hepatocellular proteins. Hepatocyte cultures were incubated with 500 μ M BNX, FLX, or IBP in the absence (control) or presence of 1 mM ABT or 10 μ M SKF-525A for 6 h. The zero time binding values were subtracted from all the data. Values are the mean $\pm$ S.D. of triplicate incubations. Note: 24-h incubation was conducted for IBP, and the effect of SKF-525A on IBP covalent protein binding was not studied.

similar formation rate versus substrate concentration profiles, with the formation of BNX-G consistently faster than that of FLX-G. Michaelis-Menten parameters (V_{max} and K_M) were determined and summarized in Table 1. The values of K_M did not appear to differ between BNX and FLX glucuronidation as a result of the high variability.

FIG. 12. The dependence of the initial rates of BNX-G (closed symbols) and FLX-G (open symbols) formation with human liver microsomes as a function of substrate concentrations. The liver microsomes were from three donors: donor 1 (▲), donor 2 (◆), and donor 3 (■).

$V_{\max}$, on the other hand, was higher for BNX glucuronidation in all three microsomal preparations.

Glucuronidation and Covalent Protein Binding of BNX and FLX in Human Hepatocyte Cultures. A pilot study was conducted in five dishes of sandwiched human hepatocyte cultures from a single donor. Both BNX-G and FLX-G were detected in the cells 6 h after they were exposed to their parent drugs at 500 μ M, with the levels of BNX-G significantly higher than FLX-G (Fig. 13). Greater amounts of covalent binding to hepatocellular proteins were also detected in the hepatocyte cultures exposed to BNX (Fig. 13). When adduct formation was normalized to the glucuronide level, BNX-protein adduct was still higher than FLX-protein adduct. This suggests that BNX is more reactive than FLX in human hepatocyte cultures.

Discussion

The major site of glucuronidation for most compounds in humans is believed to be the liver. Hepatotoxicity in elderly patients reported for BNX was the cause of its withdrawal from the world market (Dahl and Ward, 1982). The liver was also found to be a tissue targeted by both BNX and FLX *in vivo* in rats (Dong et al., 2005). Therefore, an *in vitro* model involving hepatic materials, such as intact cells or slices, may be a better method for studying the acyl glucuronide-derived drug-protein adducts than *in vitro* incubation with model proteins. Hepatocyte cultures with a sandwich configuration were selected in this study. Overlaying cultured hepatocytes with a top layer of gelled collagen or Matrigel has been shown to prolong cell viability and preserve liver-specific protein synthesis (Dunn et al., 1989, 1991; Hewitt et al., 2007), which are more stable than microsomal incubations and allow for studies of time-dependent covalent protein binding for up to 24 h. Furthermore, rat hepatocytes maintained in the sandwich configuration also re-establish a structural and functional bile canaliculus network that is usually fully developed between 3 and 7 days after the overlay (LeCluyse et al., 1994). It has been shown that the expression and function of primary active transporters, such as the canaliculus bile acid transporter and the canaliculus-multispecific organic anion transporters, were maintained in rat

sandwich-cultured hepatocytes for 96 to 120 h (Liu et al., 1999). Therefore, cultures of rat hepatocytes at 5 days after Matrigel overlay were used throughout the present study to ensure the functional hepatobiliary transport of formed acyl glucuronides across canaliculus membrane. Drug uptake and enzyme-induction potential are also better maintained in the sandwiched hepatocyte cultures (LeCluyse et al., 1994; Hewitt et al., 2007), which makes manipulation of metabolic pathways needed in the present study possible.

Three possible metabolic pathways that might lead to the covalent binding to liver proteins have been proposed for carboxylic acids (Skonberg et al., 2008), as exemplified by diclofenac, a popular model compound for studies of liver protein adducts (Hargus et al., 1994). The first pathway that involves the formation of reactive acyl glucuronide has been shown to be responsible for covalent binding of BNX, FLX, and IBP to serum albumin *in vitro* (Castillo and Smith, 1995; Dong et al., 2005) and to plasma and liver tissue proteins *in vivo* in rat (Dong et al., 2005). Acyl glucuronides may bind covalently to proteins by a transacylation mechanism and bind to the proteins via Schiff base formation after acyl migration (Smith et al., 1990; Qiu et al., 1998). The results of the present study have shown that acyl glucuronide metabolites of BNX, FLX, and IBP are formed in rat hepatocyte cultures and can bind covalently to hepatic proteins in a time- and concentration-dependent manner (Figs. 3, 4, 6, and 7). These results also indicate that BNX-G is more reactive than FLX-G and IBP-G is the least reactive metabolite, which are in agreement with both the *in vitro* studies with model proteins and the *in vivo* studies in rats (Dong et al., 2005). The proportional increases of adduct formation for BNX, FLX, and IBP as the glucuronidation increases supported the hypothesis that some part of the covalent binding of all three nonsteroidal anti-inflammatory drugs (NSAIDs) to hepatic proteins is largely acyl glucuronide-dependent (Fig. 5). Moreover, it confirmed the feasibility of using sandwich-cultured rat hepatocytes for studying glucuronidation and covalent binding to hepatocellular proteins. However, studies with the inhibitor and inducer of glucuronide conjugation reaction indicate that the formation of reactive acyl glucuronides may be only partially (~50%) responsible for the observed covalent binding of BNX, FLX, and IBP to hepatocellular proteins in hepatocyte cultures (Figs. 8 and 9).

An alternative pathway for metabolic activation involving P450 was also investigated for its role in the covalent protein adduct formation of BNX, FLX, and IBP in the rat hepatocytes. The reactive metabolites of diclofenac and acetaminophen formed by P450 have been reported to cause covalent modification of proteins (Hargus et al., 1994). Studies on the metabolism and disposition of IBP have shown that its major metabolites in plasma are carboxy- and hydroxy-IBP (Mills et al., 1973), although 13% of the dose is excreted in urine as IBP-G (Geisslinger et al., 1989). No oxidative metabolites have yet been identified for BNX and FLX in either humans or animals. However, our results of P450 inhibition studies suggested that BNX-, FLX-, or IBP-protein adduct formation *in vitro* was not likely to be mediated by oxidative metabolism (Figs. 10 and 11). Moreover, the assay of adduct by cleavage with base to liberate parent drug is unlikely to measure adducts formed by oxidative metabolism of BNX or FLX.

A third pathway that is possible for the bioactivation of NSAIDs is the formation of reactive acyl-CoA intermediate (Boelsterli, 2002; Skonberg et al., 2008). Practically all the carboxylic acids are thought to covalently modify proteins by this mechanism (Hertz and Bartana, 1988). This pathway may also lead to the inclusion of xenobiotic compounds in pathways of lipid biosynthesis (Tracy et al., 1993; Dodds, 1995). Grillo and Benet (1996) first reported in abstract form a tolmetin-glycine amino acid conjugate formed *in vitro* in freshly

TABLE 1
Michaelis-Menten parameters (V_{max} and K_M) of BNX-G and FLX-G formation in human liver microsomes

Donor	BNX			FLX		
	V_{max}	K_M	V_{max}/K_M	V_{max}	K_M	V_{max}/K_M
	nmol/mg/min	mM	$\mu\text{L}/\text{min}/\text{mg}$	nmol/mg/min	mM	$\mu\text{L}/\text{min}/\text{mg}$
1	0.865	0.322	2.69	0.223	0.136	1.64
2	1.24	0.396	3.13	0.190	0.369	0.515
3	0.049	0.286	0.171

FIG. 13. Glucuronidation and covalent protein binding of BNX (closed bars) and FLX (open bars) in human hepatocyte cultures. Human hepatocyte cultures were incubated with 500 μM BNX and FLX for 6 h; cells were washed and harvested; and BNX-G, FLX-G, and the covalent protein adducts were determined. Significantly different values obtained are the mean $\pm$ S.D. of triplicate (for BNX) or duplicate (for FLX) incubations.

isolated rat hepatocytes exposed to tolmetin. Their studies showed the chemical reactivity of xenobiotic acyl-CoAs and their potential to undergo nonenzymatic protein acylation. Sallustio et al. (2000) were the first to show a direct relationship between xenobiotic-CoA formation (in this case, nafenopin-CoA) and acylation of human liver proteins. No acyl-CoA synthase-dependent BNX, FLX, or IBP adduct formation was characterized in the present study because of a lack of specific and potent inducers or inhibitors of this metabolic pathway. However, formation of reactive NSAID-CoA intermediate may still be responsible for part of the covalent binding of BNX and FLX to hepatic proteins that are not accounted for by their reactive acyl glucuronides (Figs. 8 and 9).

Once an in vitro and in vivo correlation of relative covalent protein binding of BNX and FLX had been established using the rat as our animal model, the applicability of using sandwiched human hepatocyte cultures to investigate the glucuronidation and drug-protein adduct formation was examined. The preliminary studies showed that the in vitro methods can be applied using human tissues. Greater BNX-protein adduct was formed in human hepatocytes than FLX-protein adduct (Fig. 13), which not only agreed with their relative toxicity in humans but also was consistent with the findings in vitro using rat hepatocyte cultures. However, the enzyme kinetic studies in the small number of human liver microsomes suggested higher inter-subject variability of UGT activity in humans (Fig. 12; Table 1) than in inbred rats. With the exception of one donor who has very low UGT activity, V_{max} of BNX glucuronidation in humans (0.865 and 1.24

nmol/mg/min for donors 1 and 2, respectively) is higher than that in rats (0.30 ± 0.18 nmol/mg/min), whereas K_M values are similar in humans (0.322 and 0.396 mM for donors 1 and 2, respectively) and in rats (0.52 ± 0.43 mM). Further characterization is still needed before sandwiched human hepatocyte cultures can be used as an in vitro screening model of acyl glucuronide exposure and reactivity, although the preliminary studies look promising and suggest the method is transferable to human tissues.

In summary, the studies conducted and results obtained here show the applicability of sandwiched hepatocyte culture for estimating relative covalent binding of reactive acyl glucuronides in vivo and validated the method as a useful in vitro/in vivo model. The formation of labile and reactive acyl glucuronides was found to be at least partly responsible for approximately half of the drug-protein adduct formation in the liver tissues in vitro. Whether covalent modification of proteins in vivo leads to the observed hepatotoxicity of compounds, such as BNX, is still uncertain because of a lack of animal hepatotoxicity model for this and other drugs that form acyl glucuronides. However, preliminary studies indicate that this in vitro method is applicable to human tissue, which would provide a useful preclinical screening method to rank-order relative reactivity of acyl glucuronide metabolites of compounds containing carboxylic acid groups that are candidates in drug discovery.

Acknowledgments. We thank Dr. Edward LeCluyse for the cultured human hepatocytes and guidance in setting up the sandwiched hepatocyte culture system.

References

- Bailey MJ and Dickinson RG (2003) Acyl glucuronide reactivity in perspective: biological consequences. *Chemico-Biological Interactions* **145**:117–137.
- Boelsterli UA (2002) Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. *Curr Drug Metab* **3**:439–450.
- Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**:248–254.
- Castillo M, Lam YW, Dooley MA, Stahl E, and Smith PC (1995) Disposition and covalent binding of ibuprofen and its acyl glucuronide in the elderly. *Clin Pharmacol Ther* **57**:636–644.
- Castillo M and Smith PC (1995) Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin. *Drug Metab Dispos* **23**:566–572.
- Dahl SL and Ward JR (1982) Pharmacology, clinical efficacy, and adverse effects of the nonsteroidal anti-inflammatory agent benoxaprofen. *Pharmacotherapy* **2**:354–366.
- Dahms M and Spahn-Langguth H (1996) Covalent binding of acidic drugs via reactive intermediates: detection of benoxaprofen and flunoxaprofen protein adducts in biological material. *Pharmazie* **51**:874–881.
- Dodds PF (1995) Xenobiotic lipids: the inclusion of xenobiotic compounds in pathways of lipid biosynthesis. *Prog Lipid Res* **34**:219–247.
- Dong JQ, Etheridge AS, and Smith PC (1999) Effect of selective phase II enzyme inducers on glucuronidation of benoxaprofen in rats. *Drug Metab Dispos* **27**:1423–1428.
- Dong JQ, Liu J, and Smith PC (2005) Role of benoxaprofen and flunoxaprofen acyl glucuronides in covalent binding to rat plasma and liver proteins in vivo. *Biochem Pharmacol* **70**:937–948.
- Dunn JC, Tompkins RG, and Yarmush ML (1991) Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration. *Biotechnol Prog* **7**:237–245.
- Dunn JC, Yarmush ML, Koebe HG, and Tompkins RG (1989) Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. *FASEB J* **3**:174–177.
- Faed EM (1984) Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. *Drug Metab Rev* **15**:1213–1249.
- Geisslinger G, Dietzel K, Loew D, Schuster O, Rau G, Lachmann G, and Brune K (1989) High-performance liquid chromatographic determination of ibuprofen, its metabolites and enantiomers in biological fluids. *J Chromatogr* **491**:139–149.

- Gillette JR (1974) Commentary. A perspective on the role of chemically reactive metabolites of foreign compounds in toxicity. I. Correlation of changes in covalent binding of reactive metabolites with changes in the incidence and severity of toxicity. *Biochem Pharmacol* **23**:2785–2794.
- Grillo MP and Benet LZ (1996) In vitro studies of tolmetin metabolism in freshly isolated rat hepatocytes. Identification of a tolmetin-glycine amino acid conjugate. *ISSX Proc* **8**:228.
- Hargus SJ, Amouzede HR, Pumford NR, Myers TG, McCoy SC, and Pohl LR (1994) Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac. *Chem Res Toxicol* **7**:575–582.
- Hertz R and Bar-Tana J (1988) The acylation of proteins by xenobiotic amphipathic carboxylic acids in cultured rat hepatocytes. *Biochem J* **254**:39–44.
- Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. *Drug Metab Rev* **39**:159–234.
- LeCluyse EL, Audus KL, and Hochman JH (1994) Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. *Am J Physiol* **266**:C1764–C1774.
- Liu X, LeCluyse EL, Brouwer KR, Gan LS, Lemasters JJ, Stieger B, Meier PJ, and Brouwer KL (1999) Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. *Am J Physiol* **277**:G12–G21.
- Mills RF, Adams SS, Cliffe EE, Dickinson W, and Nicholson JS (1973) The metabolism of ibuprofen. *Xenobiotica* **3**:589–598.
- Qiu Y, Burlingame AL, and Benet LZ (1998) Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin. Studies by tandem mass spectrometry. *Drug Metab Dispos* **26**:246–256.
- Ridolfo AS, Thompkins L, Bechtol LD, and Carmichael RH (1979) Benoxaprofen, a new anti-inflammatory agent: particle-size effect on dissolution rate and oral absorption in humans. *J Pharm Sci* **68**:850–862.
- Sallustio BC, Nunthasomboon S, Drogemuller CJ, and Knights KM (2000) In vitro covalent binding of nafenopin-CoA to human liver proteins. *Toxicol Appl Pharmacol* **163**:176–182.
- Seitz S, Kretz-Rommel A, Oude Elferink RP, and Boelsterli UA (1998) Selective protein adduct formation of diclofenac glucuronide in critically dependent on the rat canalicular conjugate export pump (Mrp2). *Chem Res Toxicol* **11**:513–519.
- Sidhu JS, Farin FM, and Omiecinski CJ (1993) Influence of extracellular matrix overlay on phenobarbital-mediated induction of CYP2B1, 2B2, and 3A1 genes in primary adult rat hepatocyte culture. *Arch Biochem Biophys* **301**:103–113.
- Skonberg C, Olsen J, Madsen KG, Hansen SH, and Grillo MP (2008) Metabolic activation of carboxylic acids. *Expert Opin Drug Metab Toxicol* **4**:425–438.
- Smith PC, Benet LZ, and McDonagh AF (1990) Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism. *Drug Metab Dispos* **18**:639–644.
- Tracy TS, Wirthwein DP, and Hall SD (1993) Metabolic inversion of (R)-ibuprofen. Formation of ibuprofenyl-coenzyme A. *Drug Metab Dispos* **21**:114–120.
- Wang J, Davis M, Li F, Azam F, Scatina J, and Talaat R (2004) A novel approach for predicting acyl glucuronide reactivity via Schiff base formation: development of rapidly formed peptide adducts for LC/MS/MS measurements. *Chem Res Toxicol* **17**:1206–1216.
- Watkins JB and Klaassen CD (1983) Chemically-induced alteration of UDP-glucuronic acid concentration in rat liver. *Drug Metab Dispos* **11**:37–40.

Address correspondence to: Philip C. Smith, School of Pharmacy, CB 7360, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360. E-mail: pcs@email.unc.edu